Ro Khanna @RoKhanna
.@MazzucatoM shared that the top 19 Pharma companies in the S&P 500 index spent $300 billion —nearly 61% of R&D — on stock buybacks. Next time you hear Big Pharma say they need higher prices because they are investing in innovation, be very skeptical. — PolitiTweet.org